ProDex, Inc. (NASDAQ: PDEX) rose 27.66% to $ 0.60 on news the company released fiscal Q10 results yesterday afternoon. Despite a sales decline of 4% over the last three months of operations, and 16% decrease in sales since June 2008, the Company had gross profit for the quarter ended 30 June 2009 the increase to U.S. $ 1.9 million, 35% gross profit margin. The company also recorded a gross profit of $ 6.7 million, an increase of 32% compared to gross profit of $ 8.2 million or 33% gross profit margin last year period. Operating expenses for the fourth quarter fell 27% to U.S. $ 1.7 million compared with $ 2.2 million in the fourth quarter of 2008. The company revealed that it has a delay of 9.6 million U.S. dollars in orders and highlighted the launch of a new product is coming soon. Headquartered in Irvine, California, ProDex Inc. is a large motion control and electrical engineering by providing hightech systems and refining unit of medicine, semiconductors, dental, scientific research and aerospace markets worldwide. br Repros Therapeutics Inc. (Public, NASDAQ: RPRX) advanced 45.45% to $ 1.28 on any official news. Headquarters in The Woodlands, Texas, Repros Therapeutics is a development stage biopharmaceutical company developing drug therapies for the treatment of female pelvic serious diseases, such as treatment of uterine fibroids, anemia associated with excessive menstrual bleeding in relation with uterine fibroids, and anemia associated with uterine fibroids and endometriosis. Repros Therapeutics has three drug candidates into late stage trials. br br
